Breaking News Instant updates and real-time market news.

SDRL

Seadrill

$21.88

-0.12 (-0.55%)

, TRXC

TransEnterix

$4.45

0.01 (0.23%)

08:45
07/13/18
07/13
08:45
07/13/18
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Seadrill (SDRL) 381.30% +83.58, TransEnterix (TRXC) 55.55% +0.80, KKR (KKR) 0.74% +0.33, Pfizer (PFE) 0.41% +0.16, Yamana Gold (AUY) 0.59% +0.14, Tesla (TSLA) 1.82% +0.01, and SPDR S&P Homebuilders (XHB) 1.19% +0.01.

SDRL

Seadrill

$21.88

-0.12 (-0.55%)

TRXC

TransEnterix

$4.45

0.01 (0.23%)

KKR

KKR

$26.60

0.29 (1.10%)

PFE

Pfizer

$37.52

0.2 (0.54%)

AUY

Yamana Gold

$2.90

-0.01 (-0.34%)

TSLA

Tesla

$316.75

-1.55 (-0.49%)

XHB

SPDR Homebuilders

$40.49

0.14 (0.35%)

  • 28

    Jul

  • 22

    Aug

  • 10

    Sep

  • 01

    Oct

SDRL Seadrill
$21.88

-0.12 (-0.55%)

06/01/18
GHSC
06/01/18
UPGRADE
Target $18
GHSC
Buy
Ship Finance upgraded to Buy from Neutral at Seaport Global
Seaport Global analyst Magnus Fyhr upgraded Ship Finance (SFL) to Buy with a $18 price target saying risk/reward is increasingly attractive with several potential catalysts developing over the next few months, combined with the Seadrill (SDRL) restructuring already reflected in estimates. Fyhr said the company has ample dry powder to pursue accretive acquisitions and the current backlog provides cash flow visibility and dividend support.
TRXC TransEnterix
$4.45

0.01 (0.23%)

06/28/18
BTIG
06/28/18
DOWNGRADE
BTIG
Neutral
TransEnterix downgraded to Neutral from Buy at BTIG
BTIG analyst Sean Lavin downgraded TransEnterix to Neutral citing the "rapid" rise in shares.
05/29/18
05/29/18
DOWNGRADE
Target $4

Neutral
TransEnterix downgraded to Neutral with $4 price target at Ladenburg
As previously reported, Ladenburg analyst Jeffrey Cohen downgraded TransEnterix to Neutral from Buy citing valuation with the stock having rallied after the company received FDA approval for expanded indications that now mean the Senhance system is approved for the most commonly performed surgeries in more than 95% of hospitals nationally. Cohen raised his price target for TransEnterix to $4 from $3.50.
05/29/18
LTCO
05/29/18
DOWNGRADE
LTCO
Neutral
TransEnterix downgraded to Neutral from Buy at Ladenburg
05/29/18
STFL
05/29/18
NO CHANGE
Target $4
STFL
Buy
TransEnterix new indications double Senhance's procedure base, says Stifel
Stifel analyst Rick Wise said the FDA approval for TransEnterix to market its Senhance robotic surgical system for laparoscopic inguinal hernia and gallbladder removal came slightly earlier than expected and nearly doubles Senhance's procedure base to 3 million procedures annually. While Wise is not increasing his projections, he thinks the new "critical mass" of indications could accelerate TransEnterix's commercial adoption trajectory over time, he tells investors. The analyst keeps a Buy rating and $4 price target on TransEnterix shares.
KKR KKR
$26.60

0.29 (1.10%)

07/10/18
JMPS
07/10/18
NO CHANGE
Target $33
JMPS
Outperform
KKR price target raised to $33 at JMP Securities after 'impressive' analyst day
JMP Securities analyst Devin Ryan said KKR's investor day was "impressive" and made a compelling pitch for existing and new investors. The recurring themes were that growth opportunities abound, management views the business as at an "inflection" with even more excitement about the future, and the company is focused on simplifying its story and providing more transparency. Following the event, he increased his price target on KKR shares to $33 from $27 and maintains his Outperform rating on the stock.
07/10/18
SBSH
07/10/18
NO CHANGE
Target $31
SBSH
Buy
KKR price target raised to $31 from $28 at Citi
Citi analyst William Katz raised his price target for KKR to $31 and keeps a Buy rating on the shares following the company's investor day. The analyst believes KKR's conversion to a corporation has created a "favorable feedback loop for the sector."
07/10/18
WELS
07/10/18
NO CHANGE
Target $30
WELS
Outperform
KKR price target raised to $30 from $25 at Wells Fargo
Wells Fargo analyst Christopher Harris raised his price target for KKR to $30 from $25 after attending the company's Investor Day and as he believes the outlook appears to remain quite promising. The analyst reiterates an Outperform rating on the shares.
06/27/18
RHCO
06/27/18
NO CHANGE
Target $30
RHCO
Buy
Web.com price target raised to $30 from $24 at SunTrust
SunTrust analyst Naved Khan raised his price target on Web.com to $30, maintaining his view that the company's agreed acquisition by Siris Capital at $25 per share could generate interest from other potential buyers. Among the potential acquirers, the analyst lists Silver Lake, KKR (KKR), Vector Capital, and GoDaddy (GDDY).
PFE Pfizer
$37.52

0.2 (0.54%)

07/11/18
ARGS
07/11/18
NO CHANGE
ARGS
Hold
Pfizer valuation is appropriate, says Argus
Argus analyst David Toung kept his Hold rating on Pfizer, saying the company's valuation at 12.2-times his expected FY19 earnings - below the 12.4-times peer group average for pharmaceutical stocks - is appropriate after its revenue growth slowed in Q1. The analyst notes that higher sales from Eliquis, Ibrance, and Xejanz are being offset by declining sales of drugs faced with a loss of market exclusivity, adding that he remains concerned about competition for Pfizer's key products.
07/11/18
NEED
07/11/18
UPGRADE
Target $5
NEED
Buy
Scynexis upgraded to Buy at Needham after positive phase 2b data for SCY-078
As reported earlier, Needham analyst Alan Carr upgraded Scynexis (SCYX) to Buy from Hold with a price target of $5 after the company's positive Phase 2b trial results of oral SCY-078 in Vulvovaginal Candidiasis. The analyst notes that the data shows the 1-day 300mg BID SCY-078 is "at least equivalent and likely more effective" than the standard 150mg single dose of fluconazole made by Pfizer (PFE). Carr adds that the gastrointestinal tolerability of SCY-078 is also acceptable, which was a key concern in the earlier Phase 2a trial. The analyst further states that the new valuation accounts for expected commercialization of the drug in VVC amid a likely strong interest in a new oral agent suggested by his ObGyn survey last month.
07/11/18
WELS
07/11/18
NO CHANGE
WELS
Drug stocks may not react favorably to Pfizer price rollback, Trump tweets, says Wells Fargo
Wells Fargo analyst David Maris notes that there was widespread media coverage of drug price increases taken recently by several large cap drug companies, with President Trump criticizing Pfizer (PFE) for taking these price increases. On Tuesday, Pfizer confirmed it was rolling back its July drug price increases following a conversation with President Trump, he adds. Maris believes that drug stocks will not react favorably to this news, given the chilling effect this will likely have on others looking to take price increases. Nonetheless, the analyst points out that the price increases taken in July are only a small number of increases taken over the past year or several years, so the impact of the rollback to the healthcare system is insignificant in the big picture. Other publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
06/28/18
WELS
06/28/18
NO CHANGE
WELS
Wells says Amazon deal, Walgreens results have negative read for drug pricing
After Amazon (AMZN) agreed to acquire online pharmacy PillPack, reportedly for $1B, Wells Fargo analyst David Maris noted that he has long stated that Amazon would enter the pharmacy business and warned about the risk to drug pricing in such a scenario. Maris also noted that Walgreens (WBA) reported its U.S. retail pharmacy comparable store sales fell 1.2% in Q3, adding that retailers tend to push drugmakers on price when they feel pressure and the read-through from its report may be negative for drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
AUY Yamana Gold
$2.90

-0.01 (-0.34%)

05/03/18
MITR
05/03/18
UPGRADE
MITR
Buy
Yamana Gold upgraded to Buy from Hold at GMP Securities
04/10/18
NATB
04/10/18
UPGRADE
NATB
Outperform
Yamana Gold upgraded to Outperform from Sector Perform at National Bank
02/09/18
MACQ
02/09/18
UPGRADE
MACQ
Outperform
Yamana Gold upgraded to Outperform from Neutral at Macquarie
01/26/18
FBCO
01/26/18
UPGRADE
Target $4.25
FBCO
Outperform
Yamana Gold upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Anita Soni upgraded Yamana Gold to Outperform and raised his price target for the shares to $4.25 from $3.50. The analyst believes the company will announce better than expected guidance and has a positive view on the proposed Brio deal.
TSLA Tesla
$316.75

-1.55 (-0.49%)

07/03/18
NOMU
07/03/18
NO CHANGE
Target $450
NOMU
Buy
Tesla reestablished some credibility yesterday, says Nomura Instinet
Tesla yesterday confirmed that it hit its production target of 5,000 Model 3's in the final week of the quarter, an important milestone that reestablishes some credibility and positions the company for profitability in the second half of the year, Nomura Instinet analyst Romit Shah tells investors in a research note. The analyst, however, continues to expect Tesla shares to be volatile near term. He sees the current weakness as an opportunity to further accumulate shares and keeps a Buy rating on the name with a $450 price target. Tesla closed yesterday down $7.88 to $335.07.
07/11/18
BOFA
07/11/18
NO CHANGE
Target $180
BOFA
Buy
Tesla sees 5k per week production level as sustainable, says BofA/Merrill
BofA/Merrill analyst John Murphy kept his Buy rating and $180 price target on Tesla after hosting investor meetings with its management which included the Senior Director of Investor Relations Aaron Chews. Murphy says their presentation indicates that not only is the 5K vehicle output per week level sustainable, the company is on its way to building over 6K cars per week by Q3 and 10K per week by mid-2019. The analyst notes however that he is a bit skeptical about that forecast and believes that it will take "some time" before Model 3 output can reach "material scale". Murphy further states that Tesla's announced agreement with Shanghai government to build a factory in the region comes with an opportunity for production capacity expansion as well as a risk around funding with operating cash flows and higher prices due to U.S.-China trade friction.
07/03/18
GSCO
07/03/18
NO CHANGE
GSCO
Sell
Tesla demand data point a concern, says Goldman Sachs
Goldman Sachs analyst David Tamberrino notes that while Tesla did achieve its 5k/week production target for the Model 3, the company's Model 3 deliveries did miss the analyst's bearish estimates. Further, he sees the incremental color on Model 3 net reservations where the company showed its first declining data point as incrementally negative. Tamberrino reiterates a Sell rating on the shares.
07/10/18
KEYB
07/10/18
NO CHANGE
KEYB
Sector Weight
Tesla production potential a chance to talk bull case, says KeyBanc
After Bloomberg reported that Tesla is expected to to sign a memorandum of understanding in Shanghai to build a plant in China capable of producing 500,000 vehicle per year, KeyBanc analyst Brad Erickson told investors in a research note that "this is just the kind of announcement and scenario contemplated" in his positive near-term bias, whereby he thinks investors would attribute some incremental value associated with the incremental production well ahead of revenue. Erickson believes the company's formal messaging of China production will come before the company showing more meaningful steps toward Model 3 profitability, as a China factory will likely require an incremental capital raise. The analyst, who has a Sector Weight rating on Tesla shares, sees Tesla delivering about 426,000 vehicles at an average selling price of about $57,600 in 2020, while doing an additional $4.3B in battery revenue at an operating margin of 8%.
XHB SPDR Homebuilders
$40.49

0.14 (0.35%)

TODAY'S FREE FLY STORIES

FNWB

First Northwest Bancorp

$16.11

0.36 (2.29%)

17:48
07/20/18
07/20
17:48
07/20/18
17:48
Hot Stocks
First Northwest Bancorp names Terry Anderson chief credit officer »

First Northwest Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCX

Freeport McMoRan

$15.75

-0.05 (-0.32%)

17:42
07/20/18
07/20
17:42
07/20/18
17:42
Hot Stocks
Freeport McMoRan CAO Michael Arnold to retire »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$74.87

-0.24 (-0.32%)

, XLU

Utilities SPDR

$52.28

-0.39 (-0.74%)

17:39
07/20/18
07/20
17:39
07/20/18
17:39
General news
Week ending ETF Scorecard: Financials lead, Energy slumps »

S&P500 SECTORS:…

XLE

Energy Select Sector SPDR

$74.87

-0.24 (-0.32%)

XLU

Utilities SPDR

$52.28

-0.39 (-0.74%)

IYR

DJ US Real Estate Index Fund

$80.23

-0.68 (-0.84%)

XLP

Consumer Staples Sector SPDR

$52.84

0.3 (0.57%)

XLY

Consumer Discretionary Sector SPDR

$112.15

-0.47 (-0.42%)

XLB

S&P Select Materials SPDR

$58.31

-0.21 (-0.36%)

XLF

Financial Select Sector

$27.57

0.065 (0.24%)

XLV

Health Care Select Sector SPDR

$86.74

-0.17 (-0.20%)

XLK

Technology Select Sector SPDR

$72.55

0.01 (0.01%)

XLI

Industrial Select Sector SPDR

$74.44

-0.09 (-0.12%)

GLD

SPDR Gold Trust

$116.56

0.74 (0.64%)

SLV

iShares Silver Trust

$14.59

0.18 (1.25%)

USO

United States Oil Fund

$14.15

0.025 (0.18%)

UNG

United States Natural Gas Fund

$22.38

-0.06 (-0.27%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$85.62

0.03 (0.04%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$115.27

-0.335 (-0.29%)

TLT

iShares 20+ Year Treasury Bond Fund

$120.78

-1.46 (-1.19%)

IEF

iShares 7-10 Year Treasury Bond ETF

$102.21

-0.35 (-0.34%)

SHY

iShares 1-3 Year Treasury Bond

$83.26

-0.005 (-0.01%)

IWD

iShares Russell 1000 Value

$123.07

-0.2897 (-0.23%)

IWF

iShares Russell 1000 Growth

$149.41

-0.04 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XRX

Xerox

$25.10

-0.095 (-0.38%)

, FUJIY

Fujifilm

$0.00

(0.00%)

17:25
07/20/18
07/20
17:25
07/20/18
17:25
Hot Stocks
Xerox, Centerview settle matters related to proposed Fuji tie-up »

On July 20, 2018, Xerox…

XRX

Xerox

$25.10

-0.095 (-0.38%)

FUJIY

Fujifilm

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

STON

StoneMor Partners

$3.61

-0.015 (-0.41%)

17:15
07/20/18
07/20
17:15
07/20/18
17:15
Hot Stocks
Breaking Hot Stocks news story on StoneMor Partners »

Oaktree Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEF

Telefonica

$8.70

0.07 (0.81%)

17:11
07/20/18
07/20
17:11
07/20/18
17:11
Downgrade
Telefonica rating change at Goldman Sachs »

Telefonica downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$279.71

-0.24 (-0.09%)

, USO

United States Oil Fund

$14.15

0.025 (0.18%)

17:04
07/20/18
07/20
17:04
07/20/18
17:04
General news
Weekly CFTC Commitment of Traders highlights »

S&P500 net long 5.5K…

SPY

SPDR S&P 500 ETF Trust

$279.71

-0.24 (-0.09%)

USO

United States Oil Fund

$14.15

0.025 (0.18%)

GLD

SPDR Gold Trust

$116.56

0.74 (0.64%)

FXE

Euro Currency Trust

$112.46

0.83 (0.74%)

FXC

CurrencyShares Canadian Dollar Trust

$75.17

0.81 (1.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZWI

Citizens Community Bancorp

$14.15

(0.00%)

17:02
07/20/18
07/20
17:02
07/20/18
17:02
Syndicate
Breaking Syndicate news story on Citizens Community Bancorp »

Citizens Community…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PKD

Parker Drilling

$0.30

-0.0044 (-1.46%)

17:01
07/20/18
07/20
17:01
07/20/18
17:01
Hot Stocks
Breaking Hot Stocks news story on Parker Drilling »

Whitebox Advisors reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

RSLS

ReShape Lifesciences

$1.47

-0.02 (-1.34%)

17:00
07/20/18
07/20
17:00
07/20/18
17:00
Hot Stocks
Breaking Hot Stocks news story on ReShape Lifesciences  »

Intracoastal Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BOX

Box

$26.13

-0.26 (-0.99%)

16:57
07/20/18
07/20
16:57
07/20/18
16:57
Initiation
Box initiated at First Analysis »

Box initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALDX

Aldeyra

$7.95

-0.15 (-1.85%)

16:53
07/20/18
07/20
16:53
07/20/18
16:53
Syndicate
Breaking Syndicate news story on Aldeyra »

Aldeyra files $250M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLRE

Greenlight Capital Re

$14.00

-0.15 (-1.06%)

16:46
07/20/18
07/20
16:46
07/20/18
16:46
Hot Stocks
Greenlight Capital Re announces departure of COO »

Greenlight Capital Ry…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RVI

Retail Value

$34.56

0.2 (0.58%)

16:38
07/20/18
07/20
16:38
07/20/18
16:38
Hot Stocks
Breaking Hot Stocks news story on Retail Value »

Luxor Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LECO

Lincoln Electric

$92.26

0.64 (0.70%)

, ROK

Rockwell Automation

$171.32

-0.71 (-0.41%)

16:35
07/20/18
07/20
16:35
07/20/18
16:35
Hot Stocks
Lincoln Electric expands board to 11 directors, appoints Patrick Goris to board »

Lincoln Electric (LECO)…

LECO

Lincoln Electric

$92.26

0.64 (0.70%)

ROK

Rockwell Automation

$171.32

-0.71 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 25

    Jul

KMX

CarMax

$77.15

-0.57 (-0.73%)

16:33
07/20/18
07/20
16:33
07/20/18
16:33
Hot Stocks
CarMax chairman sells 37,500 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOW

Lowe's

$100.65

-0.74 (-0.73%)

16:31
07/20/18
07/20
16:31
07/20/18
16:31
Hot Stocks
Lowe's names Joseph McFarland as EVP of stores »

Lowe's Companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
07/20/18
07/20
16:30
07/20/18
16:30
Options
Preliminary option volume of 20.2M today »

Preliminary option volume…

PFE

Pfizer

$37.33

-0.03 (-0.08%)

16:26
07/20/18
07/20
16:26
07/20/18
16:26
Hot Stocks
FDA approves Pfizer's Biosimilar NIVESTYM for all indications »

Pfizer announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 10

    Sep

JCP

J.C. Penney

$2.50

-0.065 (-2.53%)

16:23
07/20/18
07/20
16:23
07/20/18
16:23
Hot Stocks
J.C. Penney chief customer officer McFarland to leave company »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
07/20/18
07/20
16:20
07/20/18
16:20
Options
Closing CBOE SPX and VIX Index summary for July 20th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASFI

Asta Funding

$3.15

-0.1 (-3.08%)

16:18
07/20/18
07/20
16:18
07/20/18
16:18
Hot Stocks
Asta Funding receives Nasdaq non-compliance letter »

Asta Funding announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
07/20/18
07/20
16:17
07/20/18
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
07/20/18
07/20
16:16
07/20/18
16:16
Technical Analysis
NYSE market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

16:15
07/20/18
07/20
16:15
07/20/18
16:15
Periodicals
Disney fires 'Guardians' director after controversial tweets, THR says »

Disney has fired James…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.